- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04576793
Longitudinal Imaging of Microglial Activation in Different Clinical Variants of Alzheimer's Disease (ADVISe)
The purpose of this study is to determine how inflammation is related to other changes in the brain that occur during the progression of Alzheimer's disease. The investigators are also studying how inflammation is related to the symptoms that first occur in patients with Alzheimer's disease (AD). For this reason, the investigators are asking people with different versions of Alzheimer's disease to participate. This includes patients with either:
- Posterior cortical atrophy - a version of Alzheimer's disease with vision difficulties
- Logopenic variant primary progressive aphasia - a version of Alzheimer's disease with language difficulties
- Amnestic Alzheimer's disease - a "typical" version of Alzheimer's disease with memory difficulties
- The investigators are also enrolling older adults with normal visual, language, and memory function.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is being done to learn about inflammation in Alzheimer's disease so that the investigators can find out new ways to treat patients with this disease. Because Alzheimer's disease usually causes slow changes to the brain over time, in this study the investigators are going to perform different tests and then repeat some of them two years later.
Inflammation can be measured using a type of brain scan called a positron emission tomography (PET) scan. A PET scan uses very small amounts of a radioactive drug that is injected into a vein to create a special picture of the brain. The inflammation PET scan uses a drug called ER176. ER176 is an experimental drug but has been used in several human studies before. Once in the body, ER176 sticks to areas with lots of inflammation, and the PET scan allows us to see these areas.
Inflammation can also be measured by looking at certain proteins in the spinal fluid. In order to measure these proteins in the spinal fluid, the investigators need to perform a lumbar puncture (spinal tap). Certain genes that inherited from parents influence the amount of inflammation in the body. The investigators can study how genes affect inflammation in Alzheimer's disease by looking doing genetic tests on blood that collected from the vein.
The investigators can study how genes affect inflammation in Alzheimer's disease by doing genetic tests on blood. The investigators will also be testing blood for severe acute respiratory syndrome (SARS)- CoV-2 (the virus that causes COVID-19) antibodies. The investigators want to see if exposure to the virus that causes COVID-19 changes the amount of inflammation in the brain or not.
Along with inflammation, Alzheimer's disease is also associated with the build up of the proteins amyloid and tau in the brain. The investigators can measure these proteins using PET scans. The amyloid PET scan uses a drug called florbetaben that has been approved by the FDA to help diagnose Alzheimer's disease. The tau PET scan uses a drug called MK-6240. Like ER176, MK-6240 is experimental but has been used in several human studies before.
A brain MRI creates a high resolution picture of the brain. The brain MRI helps the investigators get more information from the PET scans, and can also tell the investigators the size and appearance of different brain structures. When someone has Alzheimer's disease, some of these brain structures get smaller or have altered appearance on MRI.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Galen Ziaggi
- Phone Number: 212-305-9079
- Email: gfz2102@cumc.columbia.edu
Study Contact Backup
- Name: Elena M. Golub
- Phone Number: 212-305-9079
- Email: eg2972@cumc.columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Irving Medical Center
-
Contact:
- Aubrey S. Johnson
- Phone Number: 212-305-9079
- Email: aj2842@cumc.columbia.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Age 50 and over at time of screening.
- At screening, must have no cognitive impairment, or meet criteria for amnestic Alzheimer's disease, posterior cortical atrophy, or logopenic variant primary progressive aphasia. Diagnoses will be made based on history, exam, neuropsychological testing, brain MRI, and consensus diagnosis.
- Patients must have Clinical Dementia Rating scale score of 0.5 or 1 at enrollment. Controls must have Clinical Dementia Rating scale score of 0 at enrollment.
- Subjects unable to provide informed consent must have a surrogate decision maker.
- Written and oral fluency in English.
- Able to participate in all scheduled evaluations and to complete all required tests and procedures.
- In the opinion of the PI, the subject must be considered likely to comply with the study protocol and to have a high probability of completing the study.
Exclusion criteria:
- Past or present history of a brain disorder other than Alzheimer's disease (including presence of cortical infarct on MRI even in absence of clinical stroke).
- Serious medical conditions, which make study procedures of the current study unsafe. Such serious medical conditions include uncontrolled epilepsy and multiple serious injuries.
- Contraindication to MRI scanning.
- Conditions precluding entry into the scanners (e.g. morbid obesity, claustrophobia, etc.).
- Exposure to research related radiation in the past year that, when combined with this study, would place subjects above the allowable limits.
- Participation in the last year in a clinical trial for a disease modifying drug for AD.
- Taking immunosuppressive medication (e.g., glucocorticoids, cytostatics, antibodies, drugs acting on immunophilins, interferons, tumor necrosis factor inhibitors). Nonsteroidal anti-inflammatory drugs (NSAIDs) are not exclusionary.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: No cognitive impairment
Healthy controls
|
11C-ER176 sticks to parts of the brain where there is inflammation.
Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease.
The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
Other Names:
MK-6240 measures a protein called in the brain.
MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
Other Names:
Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease.
florbetaben measures amyloid in the brain.
Other Names:
Inflammation can also be measured by looking at certain proteins in the spinal fluid.
In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
Other Names:
|
Experimental: Cognitive impairment
|
11C-ER176 sticks to parts of the brain where there is inflammation.
Past studies have shown that inflammation is present in the brains of patients with Alzheimer's disease.
The purpose of this study is to determine if 11C-ER176 is able to accurately measure inflammation in patients with Alzheimer's disease.
11C-ER176 will be administered at activity up to 20 millicurie (mCi) per injection.
Other Names:
MK-6240 measures a protein called in the brain.
MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
Other Names:
Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease.
florbetaben measures amyloid in the brain.
Other Names:
Inflammation can also be measured by looking at certain proteins in the spinal fluid.
In order to measure these proteins in the spinal fluid, the investigators will perform a lumbar puncture (spinal tap).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
11C-ER176 Standardized Uptake Value Ratio
Time Frame: Up to 24 months
|
The standardize uptake value ratio is the concentration of radioactivity measured from the 11C-ER176 PET scan in the cortex compared to the uptake in the cerebellum (pseudo-reference region).
|
Up to 24 months
|
18F-MK6240 Standardized Uptake Value Ratio
Time Frame: Up to 24 months
|
The standardize uptake value ratio is the concentration of radioactivity measured from the 18F-MK6240 PET scan in the cortex compared to the uptake in the cerebellum (pseudo-reference region).
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: James M. Noble, MD, MS, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAS7810
- R01AG063888 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on 11C-ER176
-
Columbia UniversityCompleted
-
Columbia UniversityNational Institute on Aging (NIA)RecruitingAlzheimer DiseaseUnited States
-
National Institute of Mental Health (NIMH)TerminatedDementiaUnited States
-
Walter Reed Army Institute of Research (WRAIR)National Institute of Mental Health (NIMH); National Intrepid Center of ExcellenceRecruiting
-
Jose Gutierrez, MD, MPHEnrolling by invitationDementia | Alzheimer DiseaseUnited States
-
The University of Texas Health Science Center,...RecruitingNeuropsychiatric SyndromesUnited States
-
Mayo ClinicNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedDiabetes | Gastroparesis With Diabetes MellitusUnited States
-
Mayo ClinicEnrolling by invitationParkinson Disease | Semantic Dementia | Behavioral Variant of Frontotemporal Dementia | CBD | Apraxia of Speech | MSA - Multiple System Atrophy | FTD | PPA | PSP | PCA | LPA | Semantic AphasiaUnited States
-
Columbia UniversityRecruitingNeurodegenerative Diseases | Amyotrophic Lateral Sclerosis | Alzheimer DiseaseUnited States
-
Hoffmann-La RocheCompletedAlzheimer's Disease, Healthy VolunteerUnited States